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Conclusions: We found that dose to the intestinal cavity 
(V32Gy and V46Gy) was associated with acute diarrhea and 
chemotherapy treatment compliance in patients treated with 
IMRT for primary rectal cancer. The results are not in direct 
agreement with results from patient cohorts treated with 3D-
CRT, where V15Gy has consistently been reported as an 
optimal dose cut-off. 
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Purpose/Objective: Opinion in the literature is divided as to 
whether the LQ model of cell kill, and consequently TCP 
models based on it, are applicable for the relatively high 
dose per fraction delivered during SABR treatments of NSCLC. 
This work aimed to establish whether LQ-based TCP 
modelling can adequately describe observed local control in 
NSCLC radiotherapy for both 3D-CRT and SABR deliveries, 
through fitting model parameters to reported outcomes for 
both techniques. 
Materials and Methods: Two patient cohorts, each 
comprising approximately 25 clinical PTV DVHs, were 
constructed from retrospective clinical data for mixed-stage 
3D-CRT and stage I SABR treatments. Cohorts differed in GTV 
sizes (averaging 106 cm3 for 3D-CRT and 15 cm3 for SABR) and 
dose variation due to the lower isodose level (67 to 80% of 
isocentre dose) covering the PTV for SABR. An LQ-based TCP 
model was used to predict local control for individual PTV 
DVHs, which were then averaged over each cohort to 
estimate local control for that population. Fixed parameters 
were clonogen density within the GTV (1e7 cm-3), alpha-beta 
ratio (10 Gy), time to the onset of accelerated repopulation, 
Tk (21 days) and doubling time, Td (3.7 days). Free 
parameters fitted to published outcome data were mean 
radiosensitivity, α, and standard deviation σα. Parameters 
were fitted to reported local control at 2 years for a range of 
dose/fractionation schedules using maximum likelihood 
estimation. Best fit parameters were derived for combined 
3D-CRT and SABR outcome data and for each technique 
separately. Uncertainty estimates on derived parameter 
values were derived from likelihood profiles to assess the 
significance of parameter set differences. 
Results: Best-fit TCP model parameters (and 95% confidence 
intervals) for combined 3D-CRT and SABR cohorts were α = 
0.293 (0.286 to 0.302) Gy-1 and σα = 0.051 (0.042 to 0.067). 
Best-fit parameters resulting from separate fitting to only 3D-
CRT data fell within the 95% confidence limits of these 
values. For SABR-only fitting, α (only) fell outside this 
confidence interval; α = 0.313, σα = 0.06, however the 95% 
confidence interval on SABR-derived α (0.292 to 0.342) 
encompassed the fit to combined data. Resulting local 
control estimates are compared with the literature in the 
figure below, along with the predictions for separate model 
fitting to 3D-CRT and to SABR data. Repopulation-corrected 
equivalent 2Gy dose (EQD2) to the isocentre is used as the 
metric, indicating a smooth transition from 3D-CRT to SABR 
techniques. 
 
Conclusions: An LQ-based TCP model was found to 
adequately reproduce reported 2-year local control for both 
3D-CRT and SABR NSCLC techniques. Further, a common 
parameter set (α, σα) was found to be consistent with data 
for both techniques, despite the large dose and GTV size 
differences between patient cohorts. No significant 
advantage was found in fitting parameters to each technique 
separately.  
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Purpose/Objective: Available clinical tumour response data 
originate predominantly from homogeneous dose irradiation 
while local failure patterns were often found to be non-
homogeneously distributed in the target volume. 
Consequently, scenarios to boost the dose in high-risk regions 
have been proposed that need to be modelled 
appropriately.We propose a simple and general method to 
estimate the tumour control probability (TCP) for boost 
scenarios only based on clinical data from homogeneous dose 
prescriptions. We demonstrate its applicability for a planning 
study on 42 patients with a simultaneous integrated boost 
(SIB) for photon and proton irradiation. 
Materials and Methods: We derived a simple formalism to 
analytically determine pairs of the TCP parameters D50 (dose 
at 50% TCP) and γ50 (slope of TCP at D50) for each tumour sub-
volume according to its observed local failure probability f 
based on assumptions made by Vogelius et al. [Med.Phys. 40, 
81717, 2013]. For the case of one high-risk (H) and one low-
risk (L) tumour sub-volume the two pairs of TCP parameters 
are found to be 
 
 
They only require knowledge of clinically obtained TCP data 
D50 and γ50 for homogeneous irradiation while the parameters 
A, B, C and D depend exclusively on f. The slope is chosen to 
be the same for each sub-volume. By construction the 
product of all sub-volume TCP curves reproduces the original 
TCP curve for a homogeneous irradiation of the whole 
volume. We applied this TCP modelling approach to 42 
advanced stage head and neck cancer patients included in a 
planning study comparing four SIB scenarios per patient: two 
dose levels (2.3 Gy and 2.6 Gy), each for photon and for 
proton irradiation. A radioresistant model with D50 = 83.35 Gy 
and γ50 = 0.97 was assumed together with relative failure 
probabilities of f = 0.8 in the gross tumour volume (GTV) and 
f = 0.2 in the clinical tumour volume (CTV). 
Results: Applying the derived formulae to these input data 
yields DH50 = 75.0 Gy for the GTV and DL50 = 50.0 Gy for the 
CTV. The slope is γH/L50 = 0.70. TCP results for all four SIB 
schemata are shown in the figure for the GTV, CTV and their 
product, i.e. total TCP, including all 42 patients. The photon 
(X) and proton (P) TCP do not differ significantly despite 
higher doses for photon plans in a rim around the SIB volume. 
Dose escalation from a 2.3 Gy to a 2.6 Gy SIB resulted in an 
estimated 15 % relative increase in the median TCP from 0.42 
to 0.485, respectively. TCP modelling assuming only a single 
homogeneous dose response leads to lower total TCP and 
significant TCP differences between photon and proton plans 
for the same dose prescription. 
 
 
 
 
Conclusions: We proposed a formalism to model tumour 
response in boost scenarios which is useful for three reasons: 
It a) is given by a simple analytical expression, b) depends 
only on clinical data and c) can be applied to different 
tumour types and boost scenarios. 
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Purpose/Objective: A risk of radiation-induced cancer, 
particularly in directly irradiated tissues such as the bladder 
and rectum, has been observed in patients after prostate 
radiotherapy (RT). Risks rising to as high as 1 in 70 have been 
observed based on more than ten year follow-up of patients 
treated with older radiation techniques [Murray et al, 2014]. 
Proton therapy has a considerable potential to reduce 
integral doses with similar or improved high-dose conformity 
compared to advanced photon therapy. The aim of this study 
was to use theoretical risk models to predict how these 
characteristics of photons and protons would influence the 
risk of radiation-induced cancer to the bladder and rectum 
after RT of prostate cancer. 
Materials and Methods: Simultaneously integrated boost 
treatment plans were generated for ten prostate patients 
using both volumetric modulated arc therapy (VMAT) and 
intensity-modulated proton therapy (IMPT). Both VMAT and 
